[en] BACKGROUND: Patients with rhinitis often self-medicate with over-the-counter drugs, however this self-treating population has remained largely unstudied. OBJECTIVE: To characterize individuals self-medicating persistent rhinitis and to determine the prevalence of and risk factors for intranasal decongestant overuse within this population. METHODS: A cross-sectional observational study of individuals self-medicating persistent rhinitis (defined according to the Allergic Rhinitis and its Impact on Asthma guidelines). Participants (n = 895) completed a self-administered questionnaire to assess current symptoms, rhinitis medication, and previous physician diagnosis. Intranasal decongestant overuse was defined as daily use for at least 1 year. RESULTS: The vast majority of subjects (95%) had moderate-to-severe rhinitis. Nasal congestion was the predominant symptom (median visual analog scale, 6.6 cm; interquartile range, 3.4 cm). Sixty-five percent had had their current nasal problems for more than 5 years. Approximately 80% had a physician diagnosis (mainly allergic rhinitis or rhinosinusitis). The prevalence of intranasal decongestant overuse was high (49%), despite the fact that most of the patients (80%) were educated about the limit on duration of use. Use of intranasal glucocorticosteroids was inversely related to being an overuser (odds ratio 0.24 [95% CI, 0.17-0.35]). The risk of intranasal decongestant overuse also was reduced by use of other medications (oral H1 antihistamines and decongestants), use of nasal saline solution, and more symptoms of itchy and/or runny eyes or colored mucus. Risk was increased by a more severely blocked nose, longer duration of symptoms, the presence of sleep disturbance, higher body mass index, and previous advice to limit the duration of intranasal decongestant use. CONCLUSION: Half of the individuals self-medicating persistent rhinitis overused intranasal decongestants, despite the fact that they were educated about the limit on duration of use.
Disciplines :
Pharmacy, pharmacology & toxicology
Author, co-author :
Mehuys, Els
Gevaert, Philippe
Brusselle, Guy
Van Hees, Thierry ; Université de Liège - ULiège > Département de pharmacie > Pharmacie clinique et pharmacie hospitalière
Adriaens, Els
Christiaens, Thierry
Van Bortel, Luc
Van Tongelen, Inge
Remon, Jean-Paul
Boussery, Koen
Language :
English
Title :
Self-medication in persistent rhinitis: overuse of decongestants in half of the patients.
Publication date :
May 2014
Journal title :
Journal of Allergy and Clinical Immunology: In Practice
ISSN :
2213-2198
eISSN :
2213-2201
Publisher :
Elsevier, Amsterdam, Netherlands
Volume :
2
Issue :
3
Pages :
313-319
Peer reviewed :
Peer Reviewed verified by ORBi
Commentary :
Copyright (c) 2014 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.
Wallace D.V., Dykewicz M.S., Bernstein D.I., Blessing-Moore J., Cox L., Khan D.A., et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol 2008, 122:S1-84.
Demoly P., Allaert F.A., Lecasble M. ERASM, a pharmacoepidemiologic survey on management of intermittent allergic rhinitis in every day general medical practice in France. Allergy 2002, 57:546-554.
Maurer M., Zuberbier T. Undertreatment of rhinitis symptoms in Europe: findings from a cross-sectional questionnaire survey. Allergy 2007, 62:1057-1063.
Fromer L.M., Ortiz G., Ryan S.F., Stoloff S.W. Insights on allergic rhinitis from the patient perspective. J Fam Pract 2012, 61:S16-S22.
Storms W., Meltzer E.O., Nathan R.A., Selner J.C. Allergic rhinitis: the patient's perspective. J Allergy Clin Immunol 1997, 99:S825-S828.
Williams A., Scadding G. Is reliance on self-medication and pharmacy care adequate for rhinitis patients?. Int J Clin Pract 2009, 63:98-104.
Eickhoff C., Hammerlein A., Griese N., Schulz M. Nature and frequency of drug-related problems in self-medication (over-the-counter drugs) in daily community pharmacy practice in Germany. Pharmacoepidemiol Drug Saf 2012, 21:254-260.
Lockey R.F. Rhinitis medicamentosa and the stuffy nose. J Allergy Clin Immunol 2006, 118:1017-1018.
Graf P. Rhinitis medicamentosa: aspects of pathophysiology and treatment. Allergy 1997, 52:28-34.
NICE Clinical Knowledge Summaries. Prescribing information for intranasal decongestants. Available from: . Accessed January 7, 2014. http://cks.nice.org.uk.
Saltus R. Nasal sprays can bring on vicious cycle. The New York Times. March 14, 2006. Available from: . Accessed February 12, 2014. http://www.nytimes.com/2006/03/14/health/14spra.html?_r=0.
Bousquet J., Khaltaev N., Cruz A.A., Denburg J., Fokkens W.J., Togias A., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008, 63(Suppl 86):8-160.
Mehuys E., Paemeleire K., Van Hees T., Christiaens T., Van Bortel L.M., Van Tongelen I., et al. Self-medication of regular headache: a community pharmacy-based survey. Eur J Neurol 2012, 19:1093-1099.
Annesi-Maesano I., Didier A., Klossek M., Chanal I., Moreau D., Bousquet J. The score for allergic rhinitis (SFAR): a simple and valid assessment method in population studies. Allergy 2002, 57:107-114.
Venables K.M., Farrer N., Sharp L., Graneek B.J., Newman Taylor A.J. Respiratory symptoms questionnaire for asthma epidemiology: validity and reproducibility. Thorax 1993, 48:214-219.
Demoly P., Gauchoux R., Morera P., Touron D., Daures J.P. The place of spirometry in the diagnosis of asthma in those suffering from allergic rhinitis: a pilot study. Allergy 2005, 60:1089-1090.
Bewick V., Cheek L., Ball J. Statistics review 14: logistic regression. Crit Care 2005, 9:112-118.
Brozek J.L., Bousquet J., Baena-Cagnani C.E., Bonini S., Canonica G.W., Casale T.B., et al. Allergic Rhinitis and its Impact on Asthma (ARIA) guidelines: 2010 revision. J Allergy Clin Immunol 2010, 126:466-476.
Fokkens W.J. Who should treat patients with seasonal allergic rhinitis?. Allergy 2002, 57:469-471.
Hoffmans R., Schermer T., van Weel C., Fokkens W. Management of rhinosinusitis in Dutch general practice. Prim Care Respir J 2011, 20:64-70.
Bousquet J., Bachert C., Canonica G.W., Casale T.B., Cruz A.A., Lockey R.J., et al. Unmet needs in severe chronic upper airway disease (SCUAD). J Allergy Clin Immunol 2009, 124:428-433.
Rao V.U., Apter A.J. Steroid phobia and adherence: problems, solutions, impact on benefit/risk profile. Immunol Allergy Clin North Am 2005, 25:581-595.
Aubert-Wastiaux H., Moret L., Le Rhun A., Fontenoy A.M., Nguyen J.M., Leux C., et al. Topical corticosteroid phobia in atopic dermatitis: a study of its nature, origins and frequency. Br J Dermatol 2011, 165:808-814.
Charman C.R., Morris A.D., Williams H.C. Topical corticosteroid phobia in patients with atopic eczema. Br J Dermatol 2000, 142:931-936.
Hon K.L., Kam W.Y., Leung T.F., Lam M.C., Wong K.Y., Lee K.C., et al. Steroid fears in children with eczema. Acta Paediatr 2006, 95:1451-1455.
Hellings P.W., Dobbels F., Denhaerynck K., Piessens M., Ceuppens J.L., De Geest S. Explorative study on patient's perceived knowledge level, expectations, preferences and fear of side effects for treatment for allergic rhinitis. Clin Transl Allergy 2012, 2:9.
Lunn M., Craig T. Rhinitis and sleep. Sleep Med Rev 2011, 15:293-299.